Mendus Investor Relations Material
Latest events
Q1 2025
Mendus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mendus
Access all reports
Mendus is a biotechnology company developing immunotherapies for the treatment of cancer. The company focuses on therapies that activate the body’s immune system to target and eliminate cancer cells, based on proprietary technologies. Its operations span clinical development and research. The company is headquartered in Stockholm, Sweden, and its shares are listed on the STO.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
IMMU
Country
🇸🇪 Sweden